Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.78 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | QPCT | Q16769 | 1/20 | 0.56 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079255 | 0.81 | HRH3 (0.62) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL14415979 | 0.79 | HRH4 (0.79) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL20625882 | 0.78 | HRH3 (0.56) | HRH3HRH4MEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1696889 | 0.77 | HRH3 (0.96) | HRH3HRH4MEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1677835 | 0.76 | HRH4 (0.57) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL26267985 | 0.76 | HRH3 (0.72) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL13073926 | 0.76 | HRH3 (0.77) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL22894775 | 0.75 | HRH3 (0.52) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL14197099 | 0.75 | QPCT (0.69) | HRH3HRH4MEN1ALDH1A1MAPT | |
| SCHEMBL8963903 | 0.75 | HRH3 (0.73) | HRH3HRH4MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023005280-A1 | PREPARATION AND APPLICATION OF AMINOPYRIMIDINE DERIVATIVE SELECTIVELY TARGETING CDK9 | 中国药科大学 | 2023-02-02 | — | — | WO | disclosed |
| EP-3431469-A1 | AMIDE COMPOUND AND USE THEREOF AS AGENT FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2019-01-23 | — | — | EP | disclosed |
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| EP-3118211-A1 | AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2017-01-18 | — | — | EP | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
| US-20070060553-A1 | 3-Nitrogen-6,7-dioxygen steroids and uses related thereto | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | HRH3 145/4885HRH4 85/4885MEN1 1875/4885 |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | PKN1, PKN2, CDK9 | HRH3 3285/4885HRH4 3887/4885MEN1 1566/4885 |
| US-20070060553-A1 | 3-Nitrogen-6,7-dioxygen steroids and uses related thereto | CYP2S1, OXER1, NOS1 | HRH3 312/4885HRH4 240/4885MEN1 2759/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | HRH3 485/4885HRH4 481/4885MEN1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.